CovID Vaccine Effectiveness
Andrew Mitchell made this Official Information request to Health Research Council of New Zealand
Health Research Council of New Zealand did not have the information requested.
From: Andrew Mitchell
Dear Health Research Council of New Zealand,
1. Does the Government et al have figures from placebo-controlled, randomised and blinded scientific studies that provide statistically significant evidence that subjects treated with the substance BNT162b2 so-called (“Comirnaty-COVID-19 vaccine” from BioNTech/Pfizer”) have overall suffered fewer medically undesirable events as subjects who received this placebo, and
2. If so, what are they, and
3. What is the date of the most recent analysis of the numbers at which time the criteria of placebo-controlled, randomised and blinded were still met?
Yours faithfully,
Andrew
From: Lon Lana
Health Research Council of New Zealand
Morena Andrew
I hereby acknowledge receipt of your OIA request. We will respond within 20 working days.
Ngâ mihi
Lana Lon
Project Manager Ethics
Health Research Council of New Zealand
Te Kaunihera Rangahau Hauora o Aotearoa
PO Box 5541, Victoria Street West, Auckland, New Zealand 1142
DDI: 64 9 303 5221
Email: [email address] | http://www.hrc.govt.nz/
show quoted sections
From: Lon Lana
Health Research Council of New Zealand
Kia ora Andrew
Please find attached our repsosne to your OIA request.
Ngā mihi
Lana Lon
Project Manager Ethics
Health Research Council of New Zealand
Te Kaunihera Rangahau Hauora o Aotearoa
PO Box 5541, Victoria Street West, Auckland, New Zealand 1142
DDI: 64 9 303 5221
Email: [1][email address] | [2]www.hrc.govt.nz
show quoted sections
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence